Hsbc Holdings PLC Foghorn Therapeutics Inc. Transaction History

Hsbc Holdings PLC

  • $168 Billion
  • Q4 2024

A detailed history of Hsbc Holdings PLC transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Hsbc Holdings PLC holds 18,728 shares of FHTX stock, worth $111,618. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,728
Previous 16,667 12.37%
Holding current value
$111,618
Previous $155,000 43.23%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
BUY
$4.61 - $9.35 $9,501 - $19,270
2,061 Added 12.37%
18,728 $88,000
Q3 2024

Nov 14, 2024
BUY
$4.8 - $9.99 $3,830 - $7,972
798 Added 5.03%
16,667 $155,000
Q2 2024

Aug 12, 2024
BUY
$5.05 - $8.0 $393 - $624
78 Added 0.49%
15,869 $91,000
Q1 2024

May 15, 2024
BUY
$2.82 - $7.94 $6,212 - $17,491
2,203 Added 16.21%
15,791 $105,000
Q4 2023

Feb 12, 2024
BUY
$2.94 - $6.76 $47 - $108
16 Added 0.12%
13,588 $87,000
Q4 2022

Feb 14, 2023
BUY
$5.44 - $9.46 $16,167 - $28,115
2,972 Added 28.04%
13,572 $86,000
Q1 2022

May 16, 2022
SELL
$8.87 - $22.1 $10,076 - $25,105
-1,136 Reduced 9.68%
10,600 $163,000
Q4 2021

Feb 11, 2022
SELL
$10.79 - $22.87 $97,714 - $207,110
-9,056 Reduced 43.56%
11,736 $268,000
Q2 2021

Aug 13, 2021
BUY
$9.32 - $13.26 $19,106 - $27,183
2,050 Added 10.94%
20,792 $221,000
Q1 2021

May 14, 2021
SELL
$11.8 - $23.11 $1,864 - $3,651
-158 Reduced 0.84%
18,742 $247,000
Q4 2020

Feb 12, 2021
BUY
$15.12 - $25.88 $285,768 - $489,132
18,900 New
18,900 $383,000

Others Institutions Holding FHTX

# of Institutions
85
Shares Held
36.3M
Call Options Held
100
Put Options Held
0
View Full List

About Foghorn Therapeutics Inc.

FHTX Quotes by TradingView
  • Ticker FHTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,637,400
  • Market Cap $248M
  • Description
  • Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...
More about FHTX
Track This Portfolio

Track Hsbc Holdings PLC Portfolio

Follow Hsbc Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email